email article Neoadjuvant chemoradiotherapy (CRT) held its own on safety outcomes in a head-to-head trial against neoadjuvant chemotherapy alone for locally advanced esophageal squamous cell carcinoma (SCC), an interim analysis of a randomized study from China found. In the multicenter trial of more than 250 patients going on to minimally invasive surgery, the two approaches yielded similar rates of perioperative morbidity and mortality, as well as similar survival at 1 year, but significant histopathologic advantages emerged for the group receiving neoadjuvant CRT, reported Lijie Tan, MD, of Fudan University in Shanghai, and colleagues. While "more and more evidence has suggested the survival benefit from neoadjuvant therapy followed by surgery for locally advanced esophageal cancer," only three trials have directly compared neoadjuvant CRT and chemotherapy in this setting, the group wrote in